Micronised fenofibrate: A review of its pharmacodynamic properties and clinical efficacy in the management of dyslipidaemia

Drugs

Volumn 54, Issue 4, 1997, Pages 615-633

  Adkins, Julie C ^a   Faulds, Diana ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOTRANSFERASE; CHOLESTEROL; CREATINE KINASE; FENOFIBRATE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MICRONISED FENOFIBRATE; PRAVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

AMINOTRANSFERASE BLOOD LEVEL; ANXIETY NEUROSIS; CARDIOVASCULAR DISEASE; CHOLELITHIASIS; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; CREATINE KINASE BLOOD LEVEL; DIET THERAPY; DRUG ABSORPTION; DRUG CAPSULE; DRUG EFFICACY; DRUG FORMULATION; DRUG TOLERABILITY; DYSLIPIDEMIA; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; JAUNDICE; LIPID BLOOD LEVEL; META ANALYSIS; MORBIDITY; MORTALITY; NEUROLOGIC DISEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL DRUG ADMINISTRATION; REVIEW; SEXUAL DYSFUNCTION; SKIN DISEASE; THORAX PAIN; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 0030690553     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-199754040-00007     Document Type: Review

References (84)

1. Bulfour JA, McTavlsh D, Heel RC. Fenofibrate: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in dyslipidaemia. Drugs 1990 Aug; 40: 260-90
2. Schoonjans K, Peinado-Onsurha J, Lefehvre A-M, et al. PPARα and PPAR activators direct a distinct tissue-specific transcriptional response via a PPRE in the lipoprotein lipase gene. EMBO J 1996; 15: 101-13
3. Staels B, Vu-Dac N, Kosykh VA, et al. Fibrates downregulate apolipoprotein C-III expression independent of induction of peroxisomal acyl coenzyme A oxidase: a potential mechanism for the hypolipidemic action of fibrates. J Clin Invest 1995 Feb; 95: 705-12
4. Schoonjans K, Watanabe M, Suzuki H, et ul. Induction of the acyl-coenzyme A synthetase gene by fibrates and fatty acids is mediated by a peroxisome proliferator response element in the C promoter. J Biol Chem 1995 Aug: 270 (33): 19269-76
5. Schoonjans K, Staels B, Auwerx J. Role of the peroxisome proliferator-activated receptor (PPAR) in mediating the effects of fibrates and fatty acids on gene expression. J Lipid Res 1996; 37: 907-25
6. Schoonjans K, Staels B, Auwerx J. The peroxisome proliferator activated receptors (PPARS) and their effects on lipid metabolism and adipocyte differentiation. Biochim Biophys Acta 1996; 1302: 93-109
7. Caslake MJ, Feber MD, Foxton J, et al. Atherogenic lipoprotein phenotype in non-insulin-dependent diabetes: reversal with micronized fenofibrate [abstract]. Diabetic Med 1997 Apr; 14 Suppl. 1: S12
8. Guérin M, Bruckert É, Dolphin PJ, et al. Fenofibrate reduces plasma cholesteryl ester transfer from HDL to VLDL and normalizes the atherogenic, dense LDL profile in combined hyperlipideitiia. Arterioscler Thromb Vasc Biol 1996 Jun; 16: 763-72
9. Caslake MJ, Packard CJ, Gaw A, et al. Fenofibrate and LDL metabolic heterogeneity in hypercholesterolemia. Arterioscler Thromb 1993 May; 13: 702-11
10. Shepherd J, Caslake MJ, Lorimer AR, et al. Fenofibrate reduces low density lipoprotein catabolism in hypertriglyceridemic subjects. Arteriosclerosis 1985 Mar/Apr; 5: 162-8
11. Vu-Dac N, Schoonjans K, Laine B, et al. Negative regulation of the human apolipoprotein A-I promoter by fibrates can be attenuated by the interaction of the peroxisome proliferator-activated receptor with its response element. J Biol Chem 1994 Dec; 269 (49): 31012-8
12. Berthou L, DuvergerN, Emmanuel F, et al. Opposite regulation of human versus mouse apolipoprotein A-I by fibrates in human apolipoprotein A-I transgenic mice. J Clin Invest 1996 June; 97 (11): 2408-16
13. Vu-Dac N, Schoonjans K, Kosykh V, et al. Fibrates increase human apolipoprotein A-II expression through activation of the peroxisome proliferator-activated receptor. J Clin Invest 1995 Aug; 96: 741-50
14. McPherson R, Agnani G, Lau P, et al. Role of Lp A-I and Lp A-I/A-II in cholesteryl ester transfer protein-mediated neutral lipid transfer: studies in normal subjects and in hypertriglyceridemic patients before and after fenofibrate therapy. Arterioscler Thromb Vasc Biol 1996 Nov; 16: 1340-6
15. Farnier M, Bonnefous F, Debbas N, et al. Comparative efficacy and safety of micronized fenofibrate and simvastatin in patients with primary type IIa or IIb hyperlipidemia. Arch Intern Med 1994 Feb; 154: 441-9
16. Pfützner A, Ambrosch A, Forst T, et al. The influence of micronised fenofibrate on cardiovascular risk factors [in German]. Z Allgemeinmed 1994 Jun 20; 70: 510-5
17. Raslová K, Dubovská D, Mongiellová V, et al. Relationship between plasma fenofibric acid levels and the effect of micronized fenofibrate on cholesterol, low-density-lipoprotein cholesterol and apolipoprotein B in patients with primary hypercholesterolemia. Eur J Clin Pharmacol 1997; 52; 101-6
18. Chelly M, French Study Group, et al. Simvastatin vs. micronized fenofibrate in patients with primary hypercholesterolemia [abstract]. Atherosclerosis 1995 Jun: 115 Suppl.: S94
19. Steinmetz A, Schwartz T, Hehnke U, et al. Multicenter comparison of micronized fenofibrate and simvastatin in patients with primary type IIA or IIB hyperlipoproteinemia. J Cardiovasc Pharmacol 1996 Apr; 27: 563-70
20. Ducohu J, Vanhaelst L, Pomella D, et al. A randomised double-blind, comparative, multinational study on lipid lowering effects of 200 mg micronised fenofibrate or 20 mg pravastatin in type II dyslipidaemic patients [abstract]. 66th European Atherosclerosis Society 1996 Jul 13; Florence, 209
21. März W, Akram S, Schwarz T, et al. Micronised fenofibrate lowers LDL-cholesterol and triglycerides in patients with familial defective apolipoprotein B-100 [abstract]. XIIth International Symposium on Drugs Affecting Lipid Metabolism; 1995 Nov 7-10: Houston, Texas, USA, 112
22. Desager J-P, Horsmans Y, Vandenplas C, et al. Pharmacodynamic activity of lipoprotein lipase and hepatic lipase, and pharmacokinetic parameters measured in normolipidaemic subjects receiving ciprofibrate (100 or 200 mg/day) or micronised fenofi,rate (200 mg/day) therapy for 23 days. Atherosclerosis 1996 Jul; 124 Suppl.: S65-73
23. Perova N, Kalinina A, Paramanova I, et al. Effects of two pharmaceutical forms of fenofibrate on plasma lipoproteins in Moscow residents [abstract]. Atherosclerosis 1995 Jun; 115 Suppl.: S56
24. Idzior-Walus B, Sieradzki J, Zdzienicka A, et al. Influence of hypolipidemic treatment with fenofibrate on hemostatic factors blood pressure and insulin levels in patients with polymetabolic syndrome [abstract], Diabetologia 1996 Aug; 39 Suppl. 1: A274
25. Kornitzer M, Dramaix M, Vandenbroek MD. Efficacy and tolerance of 200 mg micronised fenofibrate administered over a 6-month period in hyperlipidaemic patients: an open Belgian multicenter study. Atherosclerosis 1994 Oct; 110 Suppl.: S49-54
26. Julius U, Schwartz T. Micronized fenofibrate in disorders of lipid metabolism [in German). Therapiewochc 1994; 44 (25): 1442-5
27. Bertolini S, Eilicio N, Daga A, et al. Effect ot single daily dose treatment of fenofibrate on plasma lipoproteins in hyperlipoproteinaemia IIb. Lur J Clin Pharmacol 1988; 34: 25-8
28. Harvengt C, Heller E, Desager JP, et al. Hypolipidemic and hypouricemic action of fenofibrate in various types of hyperlipoproteinemias. Artery 1980; 7 (1): 73-82
29. Brown WV, Dujovne CA, Farquhar JW, et al. Effects of fenofibrate on plasma lipids. Double-blind, multicenter study in patients with type IIA or IIB hyperlipidemia. Arteriosclerosis 1986 New/Dec: 6: 670-8
30. Canzler H. Bojanovski D. Lowering effect of fenofibrate (procetofene) on lipoproteins in different types of hyperlipoproteinemias. Artery 1980; 8 (2): 171-8
31. Schaefer RJ. Lamon-Fava S, Lenner JL, et al. Lipoprotein(a) levels and risk of coronary heart disease in men: the Lipid Research Clinics Coronary Primary Prevention Trial. JAMA 1994 Apr; 271 (13): 999-1003
32. Spinler SA, Cziraky MJ. Lipoprotein(A): physiologic function, association with atherosclerosis, and effects of lipid-lowering drug therapy. Ann Pharmacother 1994 Mar; 28: 343-51
33. Brown G, Albers JJ, Fisher LD, et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med 1990 Nov; 323 (19): 1289-98
34. Naito M, Hayashi T, Iguchi A. New approaches to the prevention of atherosclerosis. Drugs 1995; 50 (3): 440-53
35. Meade TW. Fibrinogen in ischaemic heart disease. Eur Heart J 1995; 16 Suppl. A: 31-5
36. Assman G, Schulte H. Identification of individuals at high risk for myocardial infarction. Atherosclerosis 1994; 110 Suppl.: S11-21
37. Persky VW, Dyer AR, Idris-Soven E, et al. Uric acid: a risk factor for coronary heart disease? Circulation 1979: 59 (5): 969-77
38. Austin MA, Breslow JL, Hennekens CH, et al. Low-density lipoprotein subclass patterns and risk ot myocardial infarction. JAMA 1988: 260 (13): 1917-21
39. Shepherd J. Mechanism of action of fibrales. Postgrad Med J 1993; 69 Suppl. 1: S34-41
40. Auwerx J, Schoonjans K, Fruchart J-C, et al. Transcriptional control of triglyceride metabolism: fibrates and fatty acids change the expression of the LPL and apo C-III genes by activating the nuclear receptor PPAR. Atherosclerosis 1996; 124 Suppl.: S29-37
41. Munoz A, Guichard JP, Reginault P. Micronised fenofibrate. Atherosclerosis 1994 Oct; 110 Suppl.: S45-48
42. Guichard JP, Levy-Prades Sauron R. A comparison of the bioavailability of standard or micronized formulations of fenofibrate. Curr Ther Res 1993 Nov; 54: 610-4
43. Desager JP, Harvengt C. Clinical pharmacokinetic study of procetofene, a new hypolipidemic drug, in volunteers. Int J Clin Pharmacol Biopharm 1978 Dec; 16: 570-4
44. März W, Schmitz H, Bach G, et al. Micronised fenofibrate: efficacy and tolerability in the treatment of isolated and combined dyslipidemia [in German]. Munch Med Wochenschr 1994; 136 (45): 50-8
45. Moisseyev VS, Ivlevu AY, Kobalava JD, et al. Effects of micronised fenofibrate in postmenopausal hypertensive women with hypercholesterolemia [abstract]. 66th European Atherosclerosis Society; 1996 Jul 13; Florence, 58
46. Lelieur I, Bonnefous F, Debbas N, et al. Efficacy and safety of a new galenic form of fenofibrale in hyperlipidemic patients during 1 year [abstract]. 9th International Symposium on Atherosclerosis: 1991 Oct 6-11; Rosemont (IL). 47
47. Kornitzer M, Dramaix M, Vandenbrock MD et al. One-year Belgian open study ot 200 mg micronised fenofibrate in 735 dyslipidaemie patients (LBOS II) [abstract]. Atherosclerosis 1995 Jun; 115 Suppl.: S134
48. Krempt M, Farmer M, Rohmer V, et al. A randomised double-blind, placebo-controlled study with micronised fenofibrate at doses ranging from 200 to 400 mg once daily in dyslipidaemic patients at high risk ol coronary heart disease [abstract]. 66th European Atherosclerosis Society; 1996 Jul 13: Florence, 217
49. Farnier M, Lenevcul-Ledoux L, French Fluvastatin Study Group. Comparison of fenofibrate monotherapy and two combined fluvastatin-fenofibrate therapy in primary hypercholesterolemia [abstract]. 66th European Atherosclerosis Society; 1996 Jul 13: Florence, 210
50. Best JD, Jerums G, Newnham HH, et al. Diabetic dyslipidaemia: Australian Diabetes Society position statement. Med J Aust 1995 Jan 16; 162: 91-3
51. Betteridge DJ. Lipids and atherogenesis in diabetes mellitus. Atherosclerosis 1996 Jul; 124 Suppl.: S43-47
52. Betteridge DJ. Diabetic dyslipidaemia: treatment implications. J Intern Med 1994 Dec; 236 Suppl. 736: 47-52
53. Feher MD, Foxton J, Curd J, et al. Total/HDL-cholesterol ratio in NIDDM: effects of micronised fenofibrate [abstract]. 66th European Atherosclerosis Society; 1996 Jul 13: Florence, 210
54. Laue C, Weber P, Fenselau S, et al. The influence of micronized fenofibrate on the postprandial lipid metabolism in NIDDM [abstract]. International Diabetes Federation Congress; 1994: Kobe, 269
55. Rudas L, Pflugfelder PW, McKenzie FN, et al. Serial evaluation of lipid profiles and risk factors for development of hyperlipidemia after cardiac transplantation. Am J Cardiol 1990 Nov; 66: 1135-8
56. Boissonnat P, Salen P, Guidollet J, et al. The long-term effects of the lipid-lowering agent fenofibrate in hyperlipidemic heart transplant recipients. Transplantation 1994 Jul 27; 58: 245-7
57. Massy ZA, Guijarro C, Kasiske BL. Effect of fenofibrates in heart transplant patients [letter]. Transplantation 1995; 59 (3): 451
58. de Lorgeril M, Boissonnat P. Effect of fenofibrates in heart transplant patients (Reply) [letter]. Transplantation 1995; 59 (3): 451-2
59. Kirchgässler KU, Schiffner-Rohe J, Stahlheber U. Cost effectiveness of micronised fenofibrate and simvastatin in the short term treatment of type IIa and type IIb hyperlipidaemia. PharmacoEconomics 1997; 12 (2 Pt 2): 237-46
60. Perreault S, Hamilton VH, Lavoie F, et al. A head-to-head comparison of the cost effectiveness of HMG-CoA reductase inhibitors and fibrates in different types of primary hyperlipidemia. Cardiovasc Drugs Ther 1996; 10: 787-94
61. Kirchgässler KU. Fenofibrate: a safety evaluation of a large German patient population. In: Gotto AM et al., editors. Multiple risk factors in cardiovascular disease. The Netherlands: Kluwer Academic Publishers and Fondazione Giovanni Lorenzini, 1995: 307-14
62. Fournier Pharmaceuticals Limited. Micronised fenofibrate prescribing information. Slough
63. Laboratoires Fournier. Micronised fenofibrate prescribing information. Dijon
64. Pyörälä K, De Backer G. Graham I, et al. Prevention of coronary heart disease in clinical practice: recommendations of the Task Force of the European Society of Cardiology. European Atherosclerosis Society and European Society of Hypertension. Atherosclerosis 1994; 110: 121-61
65. Adult Treatment Panel II. National Cholesterol Education Program. Second Report of the Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults. Circulation 1994 Mar; 89 (3): 1333-445
66. Lipid Research Clinics Program. The Lipid Research Clinics Coronary Primary Prevention Trial results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA 1984 Jan; 251 (3): 365-74
67. Lipid Research Clinics Program. The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. JAMA 1984 Jan; 251 (3): 351-64
68. Frick MH, Elo O, Haapa K, et al. Helsinki Heart Study: primary-prevention trial with gemfibrizol in middle-aged men with dyslipidemia. N Engl J Med 1987; 317: 1237-45
69. Castelli WP. The triglyceride issue: a view from Framingham. Am Heart J 1986; 112 (2): 432-7
70. Tenkanen L, Pietilä K, Manninen V, et al. The triglyceride issue revisited: findings from the Helsinki Heart Study. Arch Intern Med 1994; 154: 2714-20
71. Carlson LA, Böttiger LE, Åhfeldt P-E. Risk factors for myocardial infarction in the Stockholm prospective study. Acta Med Scand 1979; 206: 351-60
72. Havel RJ. Role of triglyceride-rich lipoproteins in progression of atherosclerosis. Circulation 1990; 81 (2): 694-6
73. NIH Consensus Development Panel on Triglyceride High-DL and CHD. Triglyceride, high-density lipoprotein, and coronary heart disease. JAMA 1993; 269 (4): 505-10
74. Hokanson JE, Austin MA. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovasc Risk 1996; 3: 213-9
75. Rosenson RS. Beyond low-density lipoprotein cholesterol. A perspective on low high-density lipoprotein disorders and Lp(a) lipoprotein excess. Arch Intern Med 1996 Jun 24; 156: 1278-84
76. Cremer P, Nagel D, Labrot B, et al. Lipoprotein Lp(a) as predictor of myocardial infarction in comparison to fibrinogen. LDL cholesterol and other risk factors: results from the prospective Göttingen Risk Incidence and Prevalence Study (GRIPS). Eur J Clin Invest 1994; 24: 444-53
77. Spencer CM, Barradell LB. Gemfibrozil: a reappraisal of its pharmacological properties and place in the management of dyslipidaemia. Drugs 1996 Jun; 51: 982-1018
78. Goa KL, Barradell LB, Plosker GL, et al. Bezafibrate: an update of its pharmacology and use in the management of dyslipidaemia. Drugs 1996 Nov; 52: 725-53
79. Farmer JA, Gotto Jr AM. Choosing the right lipid-regulating agent: a guide to selection. Drugs 1996 Nov; 52: 649-61
80. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-9
81. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995; 333: 1301-7
82. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravaslatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996; 335: 1001-9
83. Steiner G. The Diabetes Atherosclerosis Intervention Study (DAIS): a study conducted in cooperation with the World Health Organization. Diabetologia 1996 Dec; 39: 1655-61
84. Keech AC. Lipids and diabetes mellitus: an opportunity to reduce cardiovascular disease risk. 66th Congress of the European Atherosclerosis Society. New Approaches in Management of Dyslipidaemia; 1996 Jul 13-17; Florence